Regeneron pairs PD-1 latecomer with ISA’s HPV immunotherapy – FierceBiotech
FierceBiotech |
Regeneron pairs PD-1 latecomer with ISA's HPV immunotherapy
FierceBiotech … cancers like cervical and head-and-neck cancer, say the two companies. The Leiden-based company's immunotherapy is aimed at HPV16, a strain of the virus that is thought to be responsible for 55% of human cervical cancers and premalignant lesions … Regeneron and ISA Pharmaceuticals Announce Strategic Immuno-Oncology Collaboration Dutch and US Biotechs Team Up Against HPV-related Cancer Regeneron teams up with ISA Pharma to develop immunotherapeutic targeting HPV16-induced cancer |
